کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2540490 | 1122594 | 2015 | 9 صفحه PDF | دانلود رایگان |

• Quercetin prevented CCl4-induced liver injury.
• Quercetin inhibited CCl4-induced liver dysfunction and histopathologic changes.
• Quercetin inhibited oxidative stress and inflammation in livers of CCl4-treated mice.
• Quercetin decreased the TLR2/4 expression levels in liver of CCl4-treated mice.
• Quercetin inhibited the activations of MAPKs and NF-κB.
Quercetin (QE), a natural flavonoid, has many medical beneficial effects. However, its protective effects against carbon tetrachloride (CCl4) induced injury in liver have not been clarified. The aim of the present study is to illustrate the effects of QE on hepatic oxidative injury and inflammation in mice exposed to CCl4. ICR (Institute of Cancer Research) mice were exposed to CCl4 with or without QE co-administration for one week. Our results showed that QE administration significantly inhibited CCl4-induced liver injury. One of the potential mechanisms of QE action was decreasing the oxidative stress, which is consistent with decreasing of lipid peroxidation level and increasing the antioxidant enzyme activities in livers of mice. Furthermore, QE significantly decreased cytochrome P450 2E1 (CYP2E1) expression and production of pro-inflammatory markers such as inducible nitric oxide synthase (iNOS), interleukin-1β (IL-1β), cyclooxygenase-2 (COX-2) and nitric oxide (NO) in livers of CCl4-treated mouse. In the process of exploring the underlying mechanisms of QE action, we found that QE significantly inhibited the Toll-like receptor 2 (TLR2) and the Toll-like receptor 4 (TLR4) activation and mitogen-activated protein kinase (MAPK) phosphorylation, which in turn inactivated NF-κB and the inflammatory cytokines in livers of the CCl4-treated mice. In conclusion, these results suggested that the inhibition of CCl4-induced inflammation by QE is due to its anti-oxidant activity and its ability to modulate the TLR2/TLR4 and MAPK/NF-κB signaling pathway.
Journal: International Immunopharmacology - Volume 28, Issue 1, September 2015, Pages 531–539